Vanguard Personalized Indexing Management LLC Has $467,000 Stock Position in Revolution Medicines, Inc. $RVMD

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Revolution Medicines by 98.5%, now owning 12,690 shares valued at approximately $467,000.
• Analysts have a consensus rating of "Moderate Buy" for Revolution Medicines, with price targets ranging from $66.00 to $99.00.
• Revolution Medicines reported a loss of ($1.31) EPS, missing estimates but showing a revenue increase compared to the same quarter last year.

Vanguard Personalized Indexing Management LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 98.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,690 shares of the company's stock after buying an additional 6,297 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Revolution Medicines were worth $467,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Maryland State Retirement & Pension System acquired a new stake in Revolution Medicines during the second quarter worth approximately $310,000. KLP Kapitalforvaltning AS lifted its holdings in Revolution Medicines by 4.7% during the second quarter. KLP Kapitalforvaltning AS now owns 28,904 shares of the company's stock worth $1,063,000 after acquiring an additional 1,300 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Revolution Medicines by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,195 shares of the company's stock worth $265,000 after acquiring an additional 974 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Revolution Medicines during the second quarter worth $1,980,000. Finally, Clear Harbor Asset Management LLC raised its stake in shares of Revolution Medicines by 16.1% in the second quarter. Clear Harbor Asset Management LLC now owns 13,716 shares of the company's stock valued at $505,000 after buying an additional 1,905 shares during the period. 94.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on RVMD shares. Wedbush reiterated an "outperform" rating and set a $77.00 price objective on shares of Revolution Medicines in a research note on Friday, October 17th. Truist Financial initiated coverage on Revolution Medicines in a report on Friday, September 5th. They issued a "buy" rating and a $99.00 price objective for the company. Needham & Company LLC upped their price objective on Revolution Medicines from $56.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, September 11th. Mizuho initiated coverage on Revolution Medicines in a research note on Tuesday. They issued an "outperform" rating and a $90.00 target price for the company. Finally, Lifesci Capital initiated coverage on Revolution Medicines in a research report on Monday, August 18th. They set an "outperform" rating and a $80.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $77.50.

Revolution Medicines Stock Down 1.0%

Shares of NASDAQ RVMD opened at $52.98 on Thursday. The company has a 50 day simple moving average of $43.48 and a 200-day simple moving average of $39.99. The company has a market capitalization of $9.90 billion, a P/E ratio of -11.77 and a beta of 1.27. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.79 and a quick ratio of 11.79. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). The company's revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.81) EPS. On average, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Lin Wei sold 2,160 shares of Revolution Medicines stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total transaction of $98,971.20. Following the completion of the sale, the insider directly owned 88,339 shares of the company's stock, valued at approximately $4,047,692.98. The trade was a 2.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Margaret A. Horn sold 4,775 shares of Revolution Medicines stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $218,790.50. Following the sale, the chief operating officer owned 145,900 shares in the company, valued at $6,685,138. This represents a 3.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 188,033 shares of company stock worth $8,456,208. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.